Nintedanib

Nintedanib slows the deterioration of lung functionality in patients with limited cutaneous systemic sclerosis and interstitial lung disease, according to data published in Rheumatology.

Nintedanib maintains its safety and efficacy for up to 3 years in patients with systemic sclerosis-associated interstitial lung disease, according to data published the Annals of the Rheumatic Diseases.

Concomitant medication burden is associated with antifibrotic medication intolerance among patients with idiopathic pulmonary fibrosis, according to research published in Annals of the American Thoracic Society.

SAN FRANCISCO — A session at the American Thoracic Society International Conference highlighted a new clinical practice guideline addressing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults.

Nintedanib reduces the rate of forced vital capacity decline more significantly in patients with systemic sclerosis-associated interstitial lung disease who reported no dyspnea or cough at baseline, data show.

Nintedanib slows the rate of forced vital capacity decline in patients with fibrosing autoimmune disease-related interstitial lung disease, with adverse events manageable for most, according to data published in Arthritis & Rheumatology.

In a new study, concomitant medication burden was associated with antifibrotic medication intolerance in patients with idiopathic pulmonary fibrosis.

The Healio Editors compiled the most-read interstitial lung disease news published in 2021.

A speaker at the PFF Summit highlighted recent trials and therapeutic updates for progressive fibrosing interstitial lung disease.

It is likely that one or more “promising treatments” currently being investigated for Sjögren’s syndrome will come into use within the next 3 to 5 years, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.